psychotherapy assisted psilocybin: psychotherapy for patients while under the influence of psilocybin
Study summary
Obsessive-compulsive disorder (OCD) is a neuropsychiatric disorder characterized by recurrent distressing thoughts and substantial anxiety, accompanied by repetitive behaviors or mental rituals. Individuals with OCD often have diminished quality of life, and functional impairment . The disorder cause high personal, societal and economic costs . Current available treatments for OCD show moderate response rate and high rate of symptom relapse. The purpose of the current study is to explore new alternative options for the treatment of OCD that can widely and continuously benefit patients. Specifically, The aim of this study is to investigate the feasibility, safety and efficacy of psychotherapy assisted psilocybin for treatment of severe OCD. Previous research has shown safety of treatment and high efficacy in reduction of anxiety and depression symptoms. However, only one study has evaluated the use of psilocybin for OCD patients. The protocol includes 15 therapeutic sessions, of which 12 are one-hour sessions for psychological preparation and integration, and three are eight hours' experiential sessions under the influence of psilocybin. The research will include 15 participants diagnosed with severe OCD, with at least one treatment failure. Assessments will be based on comparing ratings of the main outcome measure (Y-BOCS), at baseline, at the middle and at end of treatment. Other assessments will include data on side effects- to evaluate safety, and possible spiritual variables underlying change in symptoms via standardized questionnaires.
Eligibility
Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria:
* 1\. DSM-5 diagnosis of OCD established by a trained clinician interview and confirmed by Mini International Neuropsychiatric Interview MINI (edition 7).
2\. Y-BOCS score of 16 or greater at evaluation 3. Treatment resistant- Patients; must have failed at least one medication and/or therapy trial of standard care treatment for OCD.
4\. Age: 18 Years to 65 Years 5. Has been off selective serotonin inhibitors for five half-lives of the drug plus 2 weeks.
6\. Must avoid starting new psychotherapy or psychiatric (medical) treatment during the study, without consulting the study team.
7\. Are willing to refrain from taking any psychiatric medications or recreational drugs during the study period.
8\. Must have a negative pregnancy test at study entry and prior to each experiential/ psychedelic session, if able to bear children, and must agree to use adequate birth control.
9\. Must be willing to sign a medical release form for the investigators to communicate directly with their therapist and doctors to confirm a medication and/or medical history. This is decided on a case by case basis upon the discretion of the PI.
10\. Must provide a contact (relative, spouse, close friend, or other caregiver) who is willing and able to be reached by the Clinical Investigators in the event of a participant becoming suicidal or any another relevant reason.
11\. Are willing to commit to medication dosing, experiential/ psychedelic sessions, psychotherapy and follow-up sessions and to complete the full evaluation.
Exclusion Criteria:
* 1\. Personal or immediate family history of schizophrenia, bipolar affective disorder, delusion disorder, paranoid disorder, or schizoaffective disorder.
2\. Current (or last 12-month) substance abuse disorder. 3. Unstable neurological or medical condition. 4. Active suicidal intent or last 12-month suicidal attempt. 5. A history of violence, self-harm, or harm to another. 6. Any unstable medical condition that may render study procedures unsafe. 7. Positive urine pregnancy test at the time of screening. 8. Any use of psychedelic drugs within the prior 12 months. 9. Lack of ability to sign Informed consent. Exclusion Criteria during the study
1. Any unusual reaction to any of the study procedures.
2. A participant's request to stop his/ her participation in the study.
3. Positive pregnancy test at any stage prior to the last psychedelic session
Primary outcome measure(s)
Yale-Brown Obsessive-Compulsive Scale (Y-BOCS ) change from baseline — Baseline to 6-month follow-up severity of OCD symptoms- change from baseline
Obsessive-Compulsive Inventory-Revised (OCI-R) change from baseline — Baseline to 6-month follow-up OCD symptoms
Obsessional Beliefs Questionnaire (OBQ-20) change from baseline — Baseline to 6-month follow-up obsessive Beliefs
Beck Depression Inventory -II (BDI-II) change from baseline — Baseline to 6-month follow-up depression symptoms, will be measured by the Beck Depression Inventory
Beck Anxiety Inventory (BAI) change from baseline — Baseline to 6-month follow-up anxiety symptoms will be measured by the Beck Anxiety Inventory
Mini International Neuropsychiatric Interview (M.I.N.I.) change from baseline — Baseline to end of treatment psychopathological status will be measured by the Mini International Neuropsychiatric Interview
Trial sites (1)
Facility
City
Region
Status
Beer Sheva Mental Health Center
Beersheba
Israel
Recruiting
More Beersheva Mental Health Center trials in Israel
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
